Journal Article

Adoptive T-cell therapies in neuroinfectious and neuroinflammatory diseases

Get access
Brain, Volume 149, Issue 11, November 2026, Pages 3759–3770, https://doi.org/10.1093/brain/awag275
Published:
07 August 2026
Article history
Received:
13 March 2026
Revision received:
18 June 2026
Accepted:
21 July 2026
Published:
07 August 2026
Corrected and typeset:
16 October 2026

Abstract

Immune dysfunction, spanning pathogenic autoimmunity and impaired host defence, represents a convergent mechanism across neurological autoimmune and inflammatory diseases and opportunistic infections. Despite advances in immunomodulatory and anti-infective therapies, many patients remain treatment-refractory, reflecting limitations of conventional agents. Adoptive T cell therapies introduce dynamic ‘living drugs’ capable of in vivo expansion, adaptation and persistence. These promising characteristics have led to a rapid proliferation of preliminary reports and clinical trials in inflammatory and infectious diseases of the nervous system, placing neurologists at the forefront of this evolving therapeutic landscape.

In this Update, we advance a disease-centred conceptual framework designed to reposition T cell-based therapies within neurological practice. Rather than adopting a technology-driven perspective, we organize disorders according to major patterns of immune dysfunction. Immune deficiency predisposing to opportunistic infection and immune dysregulation driving autoimmunity constitute the principal axes of neurological immune pathology. Within the autoimmune spectrum, distinct immunopathological archetypes (autoantibody-mediated, mixed B and T cell-driven, and disorders at the interface of inflammation and neurodegeneration) provide a pragmatic structure for therapeutic reasoning. Building on this classification, we delineate how adoptive T cells (chimeric antigen receptor T cells, virus-specific T cells and regulatory T cells) may be differentially aligned with underlying disease biology, linking mechanistic insight to clinical strategy.

This work is written by (a) US Government employee(s) and is in the public domain in the US.
You do not currently have access to this article.
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period